Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

被引：0

作者：

HUANG Yong-hui ^{[1
]}

CHEN Wei ^{[1
]}

LI Jia-ping ^{[1
]}

CHEN Bin ^{[1
]}

YANG Jian-yong ^{[1
]}

机构：

[1] Department of Interventional Radiology,First Affiliated Hospital of Sun Yat-sen University

来源：

中华医学杂志（英文版） | 2013年 / 126卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma(HCC)is a major threat to human health in China with high morbidity and mortality.Surgical resection and liver transplantation are the most promising treatments for HCC.The majority of patients,however,are not eligible for surgery due to advanced tumor,multifocal disease or poor liver reserve.Recently,transarterial chemoembolization(TACE)improved survival compared with best supportive care in

引用

页码：385 / 386